{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T07:38:01Z","timestamp":1771486681885,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.diagmicrobio.2018.10.019","type":"journal-article","created":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T20:10:28Z","timestamp":1541707828000},"page":"346-348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Outcomes of empiric aminoglycoside monotherapy for Pseudomonas aeruginosa bacteremia"],"prefix":"10.1016","volume":"93","author":[{"given":"Kady","family":"Phe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana R.","family":"Bowers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica T.","family":"Babic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent H.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2018.10.019_bb0005","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1128\/AAC.50.1.43-48.2006","article-title":"Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact","volume":"50","author":"Aloush","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.10.019_bb0010","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1089\/109629602762539544","article-title":"Aminoglycosides for intra-abdominal infection: equal to the challenge?","volume":"3","author":"Bailey","year":"2002","journal-title":"Surg Infect"},{"key":"10.1016\/j.diagmicrobio.2018.10.019_bb0015","author":"Bhavnani"},{"key":"10.1016\/j.diagmicrobio.2018.10.019_bb0020","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/archsurg.134.12.1293","article-title":"Analysis of aminoglycosides in the treatment of gram-negative infections in surgical patients","volume":"134","author":"Crabtree","year":"1999","journal-title":"Arch Surg"},{"key":"10.1016\/j.diagmicrobio.2018.10.019_bb0025","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/archinte.165.12.1375","article-title":"Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae: variability by site of infection","volume":"165","author":"Hyle","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.diagmicrobio.2018.10.019_bb0030","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1086\/377200","article-title":"Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome","volume":"37","author":"Kang","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.10.019_bb0035","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1086\/649021","article-title":"Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes","volume":"31","author":"Lautenbach","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.diagmicrobio.2018.10.019_bb0040","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.41.5.1127","article-title":"Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study","volume":"41","author":"Leibovici","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. C","key":"10.1016\/j.diagmicrobio.2018.10.019_bb0045","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jac\/27.suppl_C.81","article-title":"The pharmacokinetic of amikacin in critically ill adult and paediatric patients: comparison of once- versus twice-daily dosing regimens","volume":"27","author":"Marik","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.10.019_bb0050","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1128\/AAC.49.4.1306-1311.2005","article-title":"Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment","volume":"49","author":"Micek","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.10.019_bb0055","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/infdis\/155.1.93","article-title":"Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration","volume":"155","author":"Moore","year":"1987","journal-title":"J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.10.019_bb0060","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/bmj.38028.520995.63","article-title":"Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials","volume":"328","author":"Paul","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.diagmicrobio.2018.10.019_bb0065","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2165\/11594090-000000000-00000","article-title":"Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents","volume":"50","author":"Rodvold","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.diagmicrobio.2018.10.019_bb0070","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijantimicag.2015.02.009","article-title":"Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations","volume":"46","author":"Roger","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2018.10.019_bb0075","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1128\/AAC.00207-10","article-title":"Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes","volume":"54","author":"Tam","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.10.019_bb0080","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/jac\/dkm193","article-title":"Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials","volume":"60","author":"Vidal","year":"2007","journal-title":"J Antimicrob Chemother"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889318305868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889318305868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T10:43:25Z","timestamp":1565261005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889318305868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0732889318305868"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.10.019","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of empiric aminoglycoside monotherapy for Pseudomonas aeruginosa bacteremia","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}